Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05640102 · ClinicalTrials.gov registry record
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
A clinical trial of Waldenstrom Macroglobulinemia, sponsored by BeiGene.
- Recruiting
- Registry status
- 111
- Enrollment target
- 8
- Study locations
NCT05640102: Recruiting study of Waldenstrom Macroglobulinemia, sponsored by BeiGene.
NCT05640102 is a study of Waldenstrom Macroglobulinemia that is actively recruiting participants, run by BeiGene. The registered enrollment target is 111 participants, below the 470-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (76% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05640102, a study of Waldenstrom Macroglobulinemia, is actively recruiting participants, sponsored by BeiGene.
- RECRUITING
- Registry status
- 111 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this registry study will be used to better understand the clinical benefit and safety of zanubrutinib for the treatment of participants in these populations.
Primary Outcome
MRR is defined as the proportion of participants achieving either complete response (CR), very good partial response (VGPR), or partial response (PR) as determined by the investigator using an adaptation of the response criteria updated at the Sixth International Workshop on WM (IWWM)
Conditions Studied
Interventions
- DRUG Zanubrutinib
Study Locations (8)
California
- City of Hope National Medical Center - Duarte
- Los Angeles Cancer Network (Lacn) - Glendale
- Eisenhower Medical Center, Lucy Curci Cancer Center - Rancho Mirage
Alabama
- Clearview Cancer Institute - Huntsville
- South Alabama Medical Science Foundation Mitchell Cancer Institute - Mobile
Mississippi
- Hattiesburg Hematology and Oncology Clinic - Hattiesburg
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
Other
- Pan American Oncology Trials, Llc - Rio Piedras
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2023-03-03 |
| Est. Completion | 2027-12 |
What NCT05640102 shows while recruiting
NCT05640102 is an observational study that tracks outcomes without assigning an intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 470-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Waldenstrom Macroglobulinemia appearing as the primary indexed condition, and to 1 intervention - of which Zanubrutinib is the first listed.
NCT05640102 lists 8 locations in 5 states (California, Alabama, Mississippi).
Frequently Asked Questions
What is clinical trial NCT05640102 about?
NCT05640102 is a clinical study titled "Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia". This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this regi...
What is the current status of trial NCT05640102?
This trial is currently recruiting. The enrollment target is 111 participants. The study started on 2023-03-03. Estimated completion is 2027-12.
What conditions does trial NCT05640102 study?
This clinical trial studies the following conditions: Waldenstrom Macroglobulinemia.
What interventions are being tested in trial NCT05640102?
The interventions under investigation include: Zanubrutinib (DRUG).
Who is sponsoring clinical trial NCT05640102?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05640102 being conducted?
This trial has 8 study locations across Alabama, California, Mississippi, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenstrom Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05640102's enrollment target sits among peer trials
111 14th of 34 higher than 21 of 34 other Waldenstrom Macroglobulinemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Waldenstrom Macroglobulinemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RECRUITING · Phase 2
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RECRUITING
-
Study of SGR-1505 in Mature B-Cell Neoplasms
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI